The delay comes down to issues the FDA uncovered during a pre-license inspection of Novo’s Frehemgo manufacturing site after its review submission last fall. (iStock/Getty Images Plus) Already ...

On Sept. 24, Novo announced an agreement with Nanexa, a drug delivery company based in Sweden. As part of the deal, Nanexa will license its proprietary PharmaShell long-acting drug-delivery technology ...

We have already seen results from some of ribupatide's studies, including those conducted in China. And so far, it looks promising. Kailera's pipeline also includes KAI-7535, an investigational oral ...

HRS-1596 could “substantially reduce dosing frequency and improve convenience compared with current offerings,” Novo suggested. (Novo Nordisk) Novo’s ongoing attempts to rejuvenate its pipeline have ...

Novo this week laid out an ambitious strategy to reignite growth beyond its top-selling Wegovy and Ozempic injections, but faces an uphill battle to win back investors and obesity market share.

Just days after a capital-markets day left investors wondering what’s next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion. The deal announced on Thursday gives ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min North Texas could soon see two ...

Novo Nordisk (NVO) is eyeing the hair-loss market as the Ozempic maker looks to diversify as part of its post-Wegovy growth strategy, Bloomberg reported on Tuesday following an interview with its top ...

Novo Nordisk A/S is eyeing the hair-loss market as the maker of Ozempic seeks to expand its direct-to-consumer pharmaceuticals business. The condition is part of a list of areas, including addiction ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — Novo Nordisk on Monday ...

Sept 17 (Reuters) - Orbis Medicines said on Thursday it had signed a drug discovery and licensing agreement worth up to $1.4 billion with Novo Nordisk (NOVOb.CO), opens new tab to develop oral ...